- FDA Approves Expanded Injectable Treatment Formula for Smallpox-Monkeypox
- UK and Netherlands follow Belgium to implement “monkeypox quarantine”
- European EMA removes about 100 generic drugs
- EU approves AstraZeneca’s COVID-19 vaccine as booster shot
- First injection of cancer-killing oncolytic virus into human patient
- First monkeypox quarantine order: Belgium requires to self-isolate for 21 days
Only a urine sample is needed to detect the risk of prostate cancer
Only a urine sample is needed to detect the risk of prostate cancer. The University of Michigan invented a new technology for prostate cancer detection, which can detect the risk of prostate cancer with just a urine sample.
According to the “Daily Mail” report, the European Journal of Urology and Oncology recently introduced a new technique for prostate cancer detection. Urine sample testing can assess the risk of aggressive prostate cancer. The preclinical evaluation test shows that it is more specific than existing prostate cancer. Sexual antigen (PSA) detection is more accurate.
According to Dr. Simpa Salami, associate professor of urology at the University of Michigan Rogell Cancer Center and the University of Michigan School of Medicine, prostate cancer is the most common cancer among American men. It is estimated that one in eight men can be diagnosed with prostate cancer during their lifetime. In 2021, it is estimated that more than 248,000 men will be diagnosed with prostate cancer and more than 34,000 will die. Prostate cancer usually grows slowly. If detected early and confined to the prostate, there is a chance of cure.
Currently, the most common detection methods for prostate cancer are digital rectal examination and PSA examination. The specificity of the PSA test is low. If the test is abnormal, the patient needs to undergo transrectal ultrasound, magnetic resonance imaging, or prostate biopsy. However, some patients with aggressive cancer may have multiple lesions, which may be missed. It has been reported that MRI may miss 35% of the diagnosis of multifocal invasive cancer, while biopsy is expensive and prone to complications. Therefore, for aggressive prostate cancer, a more accurate and non-invasive biomarker detection method is needed.
Salami’s research team used a new detection technology-Urine Prostate Sequence Test (UPSeq) to analyze urine samples collected after male rectal testing through next-generation genome sequencing technology. The team concentrated 15 RNA transcription samples through artificial intelligence to create a liquid biopsy method that can look for specific genes in urine samples of prostate cancer patients, including PCA3 and HOXC6.
There is a set of “area under the curve” tools for assessing the detection level of prostate cancer, from a completely inaccurate “0” to a completely accurate “1” for scoring, 0.5-0.6 points pass, and 0.7-0.8 points are acceptable, and 0.8 points or more. Rated as excellent. The results showed that this urine test score was 0.82 points, compared with 0.69 points for the most commonly used PSA blood test.
Salami said that multiple areas of prostate cancer may have different cancerous states, so prostate biopsy and magnetic resonance examinations may miss evidence. In contrast, urine tests can detect the entire prostate state. This method may be used in clinical work for early cancer detection, or for long-term observation of patients with early local cancer. They can observe at first, but treatment can be initiated in time when the cancer shows signs of deterioration. Because this detection method can detect HOXB13, family members of patients with this gene also have a high risk of prostate cancer, and need to be vigilant.
Next, the researchers will continue to test and verify in more patients.
(source:internet, reference only)